ArticleBritish journal of cancer2008
Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma.
Article in British journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- The Role of the S100 Protein Family in Glioma.Journal of Cancer · 2022Review
- Review
- Review
- Heterogeneity within the PF-EPN-B ependymoma subgroup.Acta neuropathologica · 2018Article
- The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.Acta neuropathologica · 2017Article
- Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.Acta neuropathologica communications · 2016Article
- Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers.Oncogene · 2016Review
- Evaluation of chromosome 1q gain in intracranial ependymomas.Journal of neuro-oncology · 2016Article
- Article
- Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation.Brain pathology (Zurich, Switzerland) · 2012Article
- Chromosomal anomalies and prognostic markers for intracranial and spinal ependymomas.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2012Review
- Molecular genetics of ependymoma.Chinese journal of cancer · 2011Review
- Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.Cancer cell · 2011Article
- BTECH: a platform to integrate genomic, transcriptomic and epigenomic alterations in brain tumors.Neuroinformatics · 2011Article
- Clinical omics analysis of colorectal cancer incorporating copy number aberrations and gene expression data.Cancer informatics · 2010Article
- In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases.Journal of neuroinflammation · 2010Article
- Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients.Cancer immunology, immunotherapy : CII · 2009Article
- Clinical and molecular features of disseminated pediatric low-grade glioma and glioneuronal tumors: a systematic review and survival analysis.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gain of 1q is one of the most common alterations in cancer and has been associated with adverse clinical behaviour in ependymoma. The aim of this study was to investigate this region to gain insight into the role of 1q genes in intracranial paediatric ependymoma. To address this issue we generated profiles of eleven ependymoma, including two relapse pairs and seven primary tumours, using comparative genome hybridisation and serial analysis of gene expression. Analysis of 656 SAGE tags mapping to 1q identified CHI3L1 and S100A10 as the most upregulated genes in the relapse pair with de novo 1q gain upon recurrence. Moreover, three more members of the S100 family had distinct gene expression profiles in ependymoma. Candidates (CHI3L1, S100A10, S100A4, S100A6 and S100A2) were validated using immunohistochemistry on a tissue microarray of 74 paediatric ependymoma. In necrotic cases, CHI3L1 demonstrated a distinct staining pattern in tumour cells adjacent to the areas of necrosis. S100A6 significantly correlated with supratentorial tumours (P<0.001) and S100A4 with patients under the age of 3 years at diagnosis (P=0.038). In conclusion, this study provides evidence that S100A6 and S100A4 are differentially expressed in clinically relevant subgroups, and also demonstrates a link between CHI3L1 protein expression and necrosis in intracranial paediatric ependymoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.